Clinical Trial

OM336 in Seropositive Autoimmune Diseases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.
Protocol Amendment History 1 change
notable Sponsor changed: Ouro Medicines -> Lakefront Biotherapeutics West LLC 2026-07-19
Trial Details
NCT Number NCT07229144
Lead Sponsor Ouro Medicines
Conditions Sjogrens Disease, Idiopathic Inflammatory Myopathy (IIM)
Enrollment 39 participants
Start Date 2025-10-01
Primary Completion 2027-06 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-15